KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Total Liabilities (2020 - 2025)

Historic Total Liabilities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $392.0 million.

  • AbCellera Biologics' Total Liabilities rose 2453.5% to $392.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $392.0 million, marking a year-over-year increase of 2453.5%. This contributed to the annual value of $304.5 million for FY2024, which is 932.38% down from last year.
  • According to the latest figures from Q3 2025, AbCellera Biologics' Total Liabilities is $392.0 million, which was up 2453.5% from $395.0 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Total Liabilities high stood at $395.0 million for Q2 2025, and its period low was $171.4 million during Q1 2021.
  • For the 5-year period, AbCellera Biologics' Total Liabilities averaged around $310.6 million, with its median value being $314.7 million (2024).
  • Per our database at Business Quant, AbCellera Biologics' Total Liabilities surged by 12449.49% in 2022 and then tumbled by 2478.36% in 2023.
  • AbCellera Biologics' Total Liabilities (Quarter) stood at $292.8 million in 2021, then rose by 5.05% to $307.6 million in 2022, then rose by 9.15% to $335.8 million in 2023, then decreased by 9.32% to $304.5 million in 2024, then grew by 28.73% to $392.0 million in 2025.
  • Its Total Liabilities was $392.0 million in Q3 2025, compared to $395.0 million in Q2 2025 and $321.2 million in Q1 2025.